Please select a Capability in order to start your service request.
Vyntus® WALK Wirelessly Assesses Functional Exercise CapacitySep 16, 2015
SAN DIEGO, CA, Sept. 16, 2015 – CareFusion, a BD company (NYSE: BDX), announces the availability of a new respiratory diagnostics tool that is a complete mobile solution for assessing functional exercise capacity in patients.
Vyntus® WALK allows clinicians to conduct the 6-minute walk test (6MWT) fully independent of any external wires or means of connection. The application seamlessly integrates with CareFusion’s Windows-based SentrySuite diagnostic platform and software to enable further evaluation, central data management and reporting, but it also functions in standalone mode, independent of a proprietary database interface. In the latter case, reports can be printed directly from the tablet, scanned into the electronic medical record (EMR) or printed to a network PDF location.
“The Vyntus WALK has received positive reviews from patients in Europe, where the technology is already in use,” said Dan Woolson, worldwide president Respiratory Solutions for BD. “In addition, the application is workflow driven, and provides the clinician onscreen guidance to assist the patient during the test for the best possible results.”
A recommended protocol of the American Thoracic Society because it mirrors the levels of exertion typical of daily living, the 6MWT is conducted using Vyntus WALK with the patient wearing wireless sensors that communicate heart rate and SpO2 values from a wrist pulse oximeter to a tablet PC.
The clinician can also manually enter related data such as blood pressure, oxygen supply, oxygen supply type, rate of perceived exertion and BODE index.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.